Long-term safety and immunologic outcomes of daily oral immunotherapy for peanut allergy

BACKGROUND: Oral immunotherapy containing peanut (Arachis hypogaea) allergen powder-dnfp (PTAH) (Palforzia [Aimmune Therapeutics, Brisbane, Calif]) for 9 to 12 months resulted in higher tolerated amounts of peanut protein in PTAH-treated individuals aged 4 to 17 years with peanut allergy than in pla...

Descripción completa

Detalles Bibliográficos
Autores principales: Bird, J. Andrew, Nilsson, Caroline, Brown, Kari, Pham, Trinh, Tilles, Stephen, du Toit, George, Assa’ad, Amal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509957/
https://www.ncbi.nlm.nih.gov/pubmed/37779517
http://dx.doi.org/10.1016/j.jacig.2023.100120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509957/
https://www.ncbi.nlm.nih.gov/pubmed/37779517
http://dx.doi.org/10.1016/j.jacig.2023.100120

Ejemplares similares